Evidence map›Paper›PMID 25677912›Full record

ArticleDiabetes2015

GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.

Kristine Færch, Signe S Torekov, Dorte Vistisen, Nanna B Johansen, Daniel R Witte, Anna Jonsson, Oluf Pedersen, Torben Hansen, Torsten Lauritzen, Annelli Sandbæk and 2 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Diabetes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05574439 (Young Adults With Early-onset Obesity Treated With Semaglutide -The RESETTLE Study), which is not on this map. Cited by 178 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed, 1 pooled it
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05574439 phase4completedstarted 2022, after this paper: background citation

Young Adults With Early-onset Obesity Treated With Semaglutide -The RESETTLE Study

Ran2022Enrolled246Registered outcomes54Posted comparisons0ConditionsObesity, AdolescentArmsPlacebo (Semaglutide 3 mg/ml), Semaglutide 3 mg/ml, TCOC treatment
Open the trial in the graph
3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 1 synthesis or guideline pooled it, 308 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Kristine FærchSteno Diabetes Center, Gentofte, Denmark krif@steno.dk.
Signe S TorekovNNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Dorte VistisenSteno Diabetes Center, Gentofte, Denmark.
Nanna B JohansenSteno Diabetes Center, Gentofte, Denmark Danish Diabetes Academy, Odense, Denmark.
Daniel R WitteSection for General Practice, Department of Public Health, Aarhus, Denmark.
Anna JonssonNNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Oluf PedersenNNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Torben HansenNNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Torsten LauritzenSection for General Practice, Department of Public Health, Aarhus, Denmark.
Annelli SandbækSection for General Practice, Department of Public Health, Aarhus, Denmark.
Jens Juul HolstNNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Marit E JørgensenSteno Diabetes Center, Gentofte, Denmark.
University of Copenhagen · DKSteno Diabetes Center · DKDanish Diabetes Academy · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of glucose-stimulated release of GLP-1 in the development of obesity and type 2 diabetes is unclear. We assessed GLP-1 response to oral glucose in a large study population of lean and obese men and women with normal and impaired glucose regulation. Circulating concentrations of glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with normal glucose tolerance (NGT) (n = 774), prediabetes (n = 525), or screen-detected type 2 diabetes (n = 163) who attended the Danish ADDITION-PRO study (n = 1,462). Compared with individuals with NGT, women with prediabetes or type 2 diabetes had 25% lower GLP-1 response to an OGTT, and both men and women with prediabetes or type 2 diabetes had 16-21% lower 120-min GLP-1 concentrations independent of age and obesity. Obese and overweight individuals had up to 20% reduced GLP-1 response to oral glucose compared with normal weight individuals independent of glucose tolerance status. Higher GLP-1 responses were associated with better insulin sensitivity and β-cell function, older age, and lesser degree of obesity. Our findings indicate that a reduction in GLP-1 response to oral glucose occurs prior to the development of type 2 diabetes and obesity, which can have consequences for early prevention strategies for diabetes.

Indexed as

AgedAge FactorsBlood GlucoseBody Mass IndexDiabetes Mellitus, Type 2FemaleGlucagon-Like Peptide 1Glucose Tolerance TestHumansInsulinMaleMiddle AgedObesityPrediabetic StateSex CharacteristicsWaist CircumferenceBlood GlucoseGlucagon-Like Peptide 1Insulin

Identifiers

PMID25677912
OpenAlexW2081594150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.